{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T12:59:21Z","timestamp":1780750761545,"version":"3.54.1"},"publisher-location":"New York, NY","reference-count":23,"publisher":"Springer US","isbn-type":[{"value":"9781071647295","type":"print"},{"value":"9781071647301","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-1-0716-4730-1_26","type":"book-chapter","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T12:59:12Z","timestamp":1753707552000},"page":"405-420","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["In Vitro Evaluation of Antisense-Mediated Exon Inclusion for Spinal Muscular Atrophy"],"prefix":"10.1007","author":[{"given":"Aleksander","family":"Touznik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"issue":"1","key":"26_CR1","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s12041-014-0323-x","volume":"93","author":"F Cali","year":"2014","unstructured":"Cali F, Ruggeri G, Chiavetta V et al (2014) Carrier screening for spinal muscular atrophy in Italian population. J Genet 93(1):179\u2013181","journal-title":"J Genet"},{"issue":"5","key":"26_CR2","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1136\/adc.48.5.386","volume":"48","author":"A Moosa","year":"1973","unstructured":"Moosa A, Dubowitz V (1973) Spinal muscular atrophy in childhood. Two clues to clinical diagnosis. Arch Dis Child 48(5):386\u2013388","journal-title":"Arch Dis Child"},{"issue":"3","key":"26_CR3","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.pcl.2015.03.010","volume":"62","author":"BT Darras","year":"2015","unstructured":"Darras BT (2015) Spinal muscular atrophies. Pediatr Clin N Am 62(3):743\u2013766. https:\/\/doi.org\/10.1016\/j.pcl.2015.03.010","journal-title":"Pediatr Clin N Am"},{"issue":"7","key":"26_CR4","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1002\/ajmg.a.33474","volume":"152A","author":"TW Prior","year":"2010","unstructured":"Prior TW, Snyder PJ, Rink BD et al (2010) Newborn and carrier screening for spinal muscular atrophy. Am J Med Genet A 152A(7):1608\u20131616. https:\/\/doi.org\/10.1002\/ajmg.a.33474","journal-title":"Am J Med Genet A"},{"issue":"3","key":"26_CR5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s004390100473","volume":"108","author":"CF Rochette","year":"2001","unstructured":"Rochette CF, Gilbert N, Simard LR (2001) SMN gene duplication and the emergence of the SMN2 gene occurred in distinct hominids: SMN2 is unique to Homo sapiens. Hum Genet 108(3):255\u2013266","journal-title":"Hum Genet"},{"issue":"6","key":"26_CR6","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1517\/14712598.2014.896335","volume":"14","author":"A Touznik","year":"2014","unstructured":"Touznik A, Lee JJ, Yokota T (2014) New developments in exon skipping and splice modulation therapies for neuromuscular diseases. Expert Opin Biol Ther 14(6):809\u2013819. https:\/\/doi.org\/10.1517\/14712598.2014.896335","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"26_CR7","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1128\/MCB.26.4.1333-1346.2006","volume":"26","author":"NK Singh","year":"2006","unstructured":"Singh NK, Singh NN, Androphy EJ et al (2006) Splicing of a critical exon of human survival motor neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol 26(4):1333\u20131346. https:\/\/doi.org\/10.1128\/MCB.26.4.1333-1346.2006","journal-title":"Mol Cell Biol"},{"issue":"2","key":"26_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nbt0217-99","volume":"35","author":"E Dolgin","year":"2017","unstructured":"Dolgin E (2017) Spinal muscular atrophy approval boosts antisense drugs. Nat Biotechnol 35(2):99\u2013100. https:\/\/doi.org\/10.1038\/nbt0217-99","journal-title":"Nat Biotechnol"},{"issue":"15","key":"26_CR9","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1101\/gad.1941310","volume":"24","author":"Y Hua","year":"2010","unstructured":"Hua Y, Sahashi K, Hung G et al (2010) Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev 24(15):1634\u20131644. https:\/\/doi.org\/10.1101\/gad.1941310","journal-title":"Genes Dev"},{"issue":"7367","key":"26_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nature10485","volume":"478","author":"Y Hua","year":"2011","unstructured":"Hua Y, Sahashi K, Rigo F et al (2011) Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 478(7367):123\u2013126. https:\/\/doi.org\/10.1038\/nature10485","journal-title":"Nature"},{"issue":"5\u20136","key":"26_CR11","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/j.1440-1681.2006.04403.x","volume":"33","author":"JH Chan","year":"2006","unstructured":"Chan JH, Lim S, Wong WS (2006) Antisense oligonucleotides: from design to therapeutic application. Clin Exp Pharmacol Physiol 33(5\u20136):533\u2013540. https:\/\/doi.org\/10.1111\/j.1440-1681.2006.04403.x","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"5","key":"26_CR12","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.coph.2005.07.001","volume":"5","author":"A Amantana","year":"2005","unstructured":"Amantana A, Iversen PL (2005) Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers. Curr Opin Pharmacol 5(5):550\u2013555. https:\/\/doi.org\/10.1016\/j.coph.2005.07.001","journal-title":"Curr Opin Pharmacol"},{"issue":"4","key":"26_CR13","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1021\/bc0501045","volume":"16","author":"MH Nelson","year":"2005","unstructured":"Nelson MH, Stein DA, Kroeker AD et al (2005) Arginine-rich peptide conjugation to morpholino oligomers: effects on antisense activity and specificity. Bioconjug Chem 16(4):959\u2013966. https:\/\/doi.org\/10.1021\/bc0501045","journal-title":"Bioconjug Chem"},{"issue":"4","key":"26_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062114","volume":"8","author":"C Mitrpant","year":"2013","unstructured":"Mitrpant C, Porensky P, Zhou H et al (2013) Improved antisense oligonucleotide design to suppress aberrant SMN2 gene transcript processing: towards a treatment for spinal muscular atrophy. PLoS One 8(4):e62114. https:\/\/doi.org\/10.1371\/journal.pone.0062114","journal-title":"PLoS One"},{"issue":"39","key":"26_CR15","doi-asserted-by":"publisher","first-page":"10962","DOI":"10.1073\/pnas.1605731113","volume":"113","author":"SM Hammond","year":"2016","unstructured":"Hammond SM, Hazell G, Shabanpoor F et al (2016) Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy. Proc Natl Acad Sci USA 113(39):10962\u201310967. https:\/\/doi.org\/10.1073\/pnas.1605731113","journal-title":"Proc Natl Acad Sci USA"},{"issue":"14","key":"26_CR16","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1001\/jama.2017.2601","volume":"317","author":"SF Nelson","year":"2017","unstructured":"Nelson SF, Miceli MC (2017) FDA approval of Eteplirsen for muscular dystrophy. JAMA 317(14):1480. https:\/\/doi.org\/10.1001\/jama.2017.2601","journal-title":"JAMA"},{"key":"26_CR17","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/DDDT.S97635","volume":"11","author":"KR Lim","year":"2017","unstructured":"Lim KR, Maruyama R, Yokota T (2017) Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Devel Ther 11:533\u2013545. https:\/\/doi.org\/10.2147\/DDDT.S97635","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"26_CR18","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/jpm3030144","volume":"3","author":"JJ Lee","year":"2013","unstructured":"Lee JJ, Yokota T (2013) Antisense therapy in neurology. J Pers Med 3(3):144\u2013176. https:\/\/doi.org\/10.3390\/jpm3030144","journal-title":"J Pers Med"},{"issue":"9","key":"26_CR19","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1093\/nar\/30.9.1911","volume":"30","author":"J Kurreck","year":"2002","unstructured":"Kurreck J, Wyszko E, Gillen C et al (2002) Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res 30(9):1911\u20131918","journal-title":"Nucleic Acids Res"},{"issue":"42","key":"26_CR20","doi-asserted-by":"publisher","first-page":"13233","DOI":"10.1021\/bi0485732","volume":"43","author":"B Vester","year":"2004","unstructured":"Vester B, Wengel J (2004) LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA. Biochemistry 43(42):13233\u201313241. https:\/\/doi.org\/10.1021\/bi0485732","journal-title":"Biochemistry"},{"key":"26_CR21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/978-1-4939-7374-3_10","volume":"1687","author":"T Shimo","year":"2018","unstructured":"Shimo T, Maruyama R, Yokota T (2018) Designing effective antisense oligonucleotides for exon skipping. Methods Mol Biol 1687:143\u2013155. https:\/\/doi.org\/10.1007\/978-1-4939-7374-3_10","journal-title":"Methods Mol Biol"},{"issue":"1","key":"26_CR22","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1038\/s41598-017-03850-2","volume":"7","author":"A Touznik","year":"2017","unstructured":"Touznik A, Maruyama R, Hosoki K et al (2017) LNA\/DNA mixmer-based antisense oligonucleotides correct alternative splicing of the SMN2 gene and restore SMN protein expression in type 1 SMA fibroblasts. Sci Rep 7(1):3672. https:\/\/doi.org\/10.1038\/s41598-017-03850-2","journal-title":"Sci Rep"},{"issue":"12","key":"26_CR23","doi-asserted-by":"publisher","first-page":"8174","DOI":"10.1093\/nar\/gku512","volume":"42","author":"T Shimo","year":"2014","unstructured":"Shimo T, Tachibana K, Saito K et al (2014) Design and evaluation of locked nucleic acid-based splice-switching oligonucleotides in vitro. Nucleic Acids Res 42(12):8174\u20138187. https:\/\/doi.org\/10.1093\/nar\/gku512","journal-title":"Nucleic Acids Res"}],"container-title":["Methods in Molecular Biology","Exon Skipping and Inclusion Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-4730-1_26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T12:08:03Z","timestamp":1780747683000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-4730-1_26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9781071647295","9781071647301"],"references-count":23,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-4730-1_26","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"29 July 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}